[Proceedings: Clinical experiences with a new beta adrenergic blocking agent KO 1366 (0-[2-hydroxy-3-(tertiarybutylamino)-propoxy]-benzonitrile-hydrochloride)].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D011412:Propanolamines / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D011433:Propranolol